Central Serous Chorioretinopathy（CSC） - Medical Tourism & Treatment Guide in China

Central Serous Chorioretinopathy (CSCR) is a vision-threatening retinal disorder characterized by the accumulation of serous fluid beneath the neurosensory retina, typically in the macular region. It predominantly affects healthy, middle-aged men and is associated with stress, corticosteroid use, and systemic hypertension. The pathophysiology involves dysfunction of the retinal pigment epithelium (RPE) and choroidal hyperpermeability, leading to focal leakage from the choriocapillaris. Acute CSCR often resolves spontaneously within three to six months, but chronic or recurrent cases may result in persistent subretinal fluid, RPE atrophy, photoreceptor damage, and irreversible central vision loss. Diagnosis relies on multimodal imaging—including spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and indocyanine green angiography (ICGA)—to identify leakage points and assess choroidal vascular abnormalities. Treatment indications include persistent fluid beyond three months, recurrent episodes, or declining visual acuity; options range from observation and lifestyle modification to targeted photodynamic therapy (PDT), micropulse laser, or emerging anti-VEGF and mineralocorticoid receptor antagonist therapies.

China offers distinct advantages for international patients seeking CSCR management. Leading ophthalmology centers—such as those affiliated with Peking University People’s Hospital and Shanghai First People’s Hospital—boast internationally trained retinal specialists with extensive experience in complex CSCR cases, including refractory and chronic forms. These institutions utilize state-of-the-art imaging platforms (e.g., swept-source OCT-angiography, ultra-widefield ICGA) and precision laser systems enabling personalized, minimally invasive interventions. Clinical outcomes align with global benchmarks: over 85% of treated patients achieve complete fluid resolution and stabilized or improved best-corrected visual acuity within six months. Crucially, treatment costs in China are typically 40–60% lower than in the US, UK, or Germany, without compromising clinical rigor or safety standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients—handling hospital referrals, coordinating pre-arrival diagnostics, ensuring transparent all-inclusive pricing, and providing end-to-end support from visa assistance to post-treatment follow-up coordination.